Current Editions
Tale of two WRN inhibitors: a covalent and a non-covalent molecule enter the clinic
As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
Product Development
Product Development
An ASGCT preview; plus the latest in accelerated approval and Biosecure — a BioCentury podcast
An explosion of CAR T applications among key themes at this year’s ASGCT meeting
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
Management Tracks
Pfizer taps Citi’s Baum for C-level pipeline management and strategy role
Plus: Radiotherapy play Ratio gets new COO, CFO; and updates from Araceli, Kezar and Hercules
BioCentury ISSN 1097-7201